
Privium Fund Bets $5M on Denali Ahead of FDA Approval Win
Privium Fund Management acquires $5.07M stake in Denali Therapeutics following FDA approval of first commercial drug Avlayah for Hunter syndrome treatment.
DNLIclinical trialsneurodegenerative diseases